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Abtract 
Meloxicam is the most commonly prescribed non-steroidal anti-inflammatory drug. In this study, a simple, rapid and 
cost-effective method for the analysis of meloxicam and its major metabolites (5-hydroxy meloxicam and 5-carboxy 
meloxicam) in biological fluids (human plasma, urine and saliva) was developed and validated using RP-HPLC 
coupled with UV detector. The samples were analyzed by injecting 20 µl into the HPLC system using supelco 
analytical C18 (150 mm ×4.6 mm, 5 µm) column, protected by a C18 (30 mm×4.6 mm, 10 µm) Perkin Elmer, guard 
column. The mobile phase methanol: TFA (0.05% aqueous solution) in 60:40%v/v was pumped with a flow rate of 
1.3 mL/min at ambient temperature and the eluents were checked at 353nm using Piroxicam as internal standard. 
Meloxicam and the metabolites were extracted from biological fluids using dichloromethane and the percent 
recovery for meloxicam, 5-hydroxy meloxicam and 5-carboxy meloxicam were 98.8%, 97.3%, 97% in plasma, 99%, 
98.6%, 95.1% in urine and 95.8%, 92.9%, 92.7% in saliva, respectively. The limits of detection of meloxicam, 5-
hydroxy meloxicam and 5-carboxy meloxicam were 3 ng, 10 ng and 8 ng, whereas limit of quantification were 9 ng, 
30 ng and 25 ng, respectively. The method was linear over the concentration range of 10 - 2000 ng/mL for 
meloxicam, 30 - 1000 ng/mL, 25 - 1000 ng/mL for 5-hydroxy meloxicam and 5-carboxy meloxicam, respectively. 
The developed method was validated according to standard guidelines, various experimental parameters and 
chromatographic conditions such as mobile phase composition, flow rate, linearity, accuracy, precision, sensitivity 
etc. were optimized and were successfully applied for the pharmacokinetic studies in the plasma samples of the 
healthy human volunteers. 
1. Introduction 
Meloxicam [4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide] a 
yellow crystalline powder, with a molecular weight of 351.40 g/mole and is insoluble in water, with a slightly 
solubility in organic solvents i.e. methanol and ethanol [1, 2]. Chemical structure of meloxicam and its major 
metabolites are presented in Fig-1. 
Meloxicam is an NSAID from oxicam group, it preferentially inhibit cyclooxygenase-2 (COX-2) with comparative to 
cyclooxygenase-1(COX-1) [3]. Unlike other NSAIDs, meloxicam is gentle on stomach with low ulcer-genic 
property, due to lower affinity for COX-1 [4]. It is mainly used in the management of ankylosing spondylitis, 
arthritis, rheumatoid arthritis, and other rheumatologic conditions [5].The bioavailability of meloxicam is 89% and 
99% of the absorbed drug bind to the plasma protein, the peak plasma concentration is achieved in 5 ± 6 hours and 
elimination half-life is about 20 hours [6-9].It is metabolized by the hepatic CYP2C9 and to a lesser extent by 
CYP3A4 to 5-hydroxy meloxicam which is further converted to 5-carboxy meloxicam [9, 10] that are rapidly 
excreted in urine [8]. Whole of administered meloxicam  is excreted as metabolites in urine and in feces and only 
minimal amounts of parent drug can be detected in urine and in feces [11]. 
Several methodical approaches have been reported for the analysis of meloxicam in the biological samples, these 
techniques include HPLC and LCMS. Reported methods applied advanced detectors like diode array detector and 
mass spectrometry [12 -14], which are not readily and easily available. Moreover, mobile phase composition used in 
all of the methods is complex, consisting of buffers which can affect the column life and processing time [12, 15, 
16]. Extraction of meloxicam from biological samples is a tedious job and most of the methods have used large 
volumes of plasma without any proper extraction procedure [4, 13]. Not a single method of HPLC for the 
simultaneous analysis of meloxicam and its metabolites (5-hydroxy meloxicam and 5-carboxy meloxicam) has been 
reported in biological fluids. There is a need to develop a validated, sensitive, easy and rapid method for the 
estimation of meloxicam and its metabolites in biological samples, particularly for the pharmacokinetic studies. 
In the presented study, suitable extraction procedure has been developed for extraction of meloxicam and its 
metabolites from biological samples. The developed method is a novel one with respect to mobile phase composition 
and shorter analysis time. The suggested method was then successfully applied for the routine analysis of meloxicam 
and its metabolites in pharmacokinetics study of the drug.  
2. Experimental 
2.1. Chemicals 
Meloxicam was provided by Sigma Aldrich, 5-carboxy meloxicam and 5-hydroxy meloxicam was purchased from 
Toronto Research Chemicals (Canada), Piroxicam was a kind gift from Medicraft Pharmaceuticals (Peshawar, 
Pakistan). The analytical grade HPLC solvents Methanol, Trifluroacetic-acid (TFA) and dichloromethane were 
procured from Sigma Aldrich (Oslo, Norway). Freshly, double distilled and deionized HPLC grade water was 
obtained from Millipore distillation apparatus (Milford, USA). 
(TXLSPHQW¶V 
The analysis were performed using HPLC system (Perkin Elmer Series 200, Norwalk, USA) consisting of a pump, 
FROXPQRYHQ89GHWHFWRUDYDFXXPGHJDVVHUDUKHRG\QHPDQXDOLQMHFWRUZLWKȝ/ORRSwhich is linked to a Pe 
Nelson NCI-900. The chromatographic setup was run by a Total Chrome Workstation (version 6.3.1) Perkin Elmer 
software for the solicitation and proceeding of data. The column used for analysis of the drug was Supelco C18 
reverse phase HPLC column (150mm x 4.6mm ,5µm) and guarded by RP Perkin Elmer C18 (30mm × 4.6mm, 
10µm; Norwalk, USA) column. Supel clean SPE cartridges LC-18 (1ml; particle size 56.2µm; Bellefonte, USA) with 
the VisiprepTM manifold vacuum were used for solid-phase extraction. A Schimadzu (AX 200) electronic balance, 
temperature controlled centrifuge machine (model: k-2080, Centurion, UK) was used.   
2.3. Chromatographic conditions 
The mobile phase was comprised of methanol: 0.05% TFA (60:40% v/v), pumped at the flow rate of 1.3ml/min. 
These solvents were filtered through membrane (0.2µm) and degassed by ultra-sonication. Piroxicam was used as 
internal standard and the eluents were monitored at 353 nm. 
 
2.4. Preparation of standard solutions 
The standard stock solution of meloxicam (0.5mg/ml) were prepared in methanol containing 20µl of glacial acetic 
acid. The standard stock solution of 5-hydroxy meloxicam, 5-carboxy meloxicam and piroxicam (0.5mg/ml) were 
also prepared in methanol, DMF (dimethyl-form-amide) and methanol, respectively and further dilutions were 
prepared using mobile phase. 
The working solutions of meloxicam (10, 50, 100, 250, 500, 1000, 1500, 2000ng/ml) were prepared by diluting the 
standard secondary stock solution of meloxicam (10µg/ml). The working standard solutions of 5-carboxy meloxicam 
(25, 50, 75, 100, 250, 500, 750, 1000 ng/ml), 5-hydroxy meloxicam (30, 50, 75, 100, 250, 500, 750, 1000ng/ml) and 
that of piroxicam (1000ng/ml) were prepared from their respective standard secondary stock solution (10µg/ml) and 
were stored at refrigerator temperature.  
2.5. Sample collection and preparation 
The study was approved by the Ethical Committee of the Department of Pharmacy, University of Peshawar and 
informed written assent was attained from the recruited healthy human volunteers, aged between 25 to 35 years and 
BMI in the range of 23-30. The volunteers were instructed to avoid any medicine for two weeks prior to the study. 
Early morning at fasting condition, a single oral dose of the meloxicam was taken orally with a JODVVRIZDWHU§
ml) and blood (2ml), urine (20 ml), saliva samples (3 ml) were collected periodically, centrifuged at 3000 rpm for 10 
min; transferred into eppendorf tubes and stored at -20 oC till analysis. 
The blank biological fluids (collected before administration of the drug) were thawed at room temperature, at the 
time of analysis and spiked with appropriate concentration of working solution of meloxicam (i.e., 10, 50, 100, 250, 
500, 1000, 1500, 2000 ng/ml), 5-hydroxy meloxicam (i.e., 30, 50, 75, 100, 250, 500, 750, 1000ng/ml), 5-carboxy 
meloxicam (i.e., 25, 50, 75, 100, 250, 500, 750, 1000 ng/ml) and piroxicam (internal standard) to obtain calibration 
standards.  
 
 
2.6. Extraction of meloxicam and its metabolites from biological samples 
Liquid-liquid and solid-phase extraction were assessed for the recovery of parent drug and its metabolites from 
biological samples. 
2.6.1. Liquid-liquid extraction  
Biological fluids (200µl) were mixed with internal standard (100µl = 100ng) in eppendorf tube, acetonitrile (600µl) 
was added and vortexed for 3min.  Then dichloromethane (1100µl) was added, further vortexed for 5min, centrifuged 
for 15min at 9000 rpm, organic layer collected and was evaporated under the gentle stream of nitrogen. The residues 
were re-dissolved in methanol (2ml) and injected into HPLC for analysis.  
2.6.2. Solid phase extraction (SPE) 
SPE procedure was also utilized for the biological samples in order to achieve good recovery of analytes and 
comparison between the two methods. In SPE, first conditioning of the cartridge was carried out using methanol (1 
ml) followed by equilibration with 1ml of water. The biological sample (200 µl) containing  internal standard (100 
µl), water (3 ml), concentrated HCl (10 µl) were transferred into the cartridge and forced through it by applying 
vacuum, washed with water (2 ml), dried by air and then dichloromethane (1 ml) was used to elute the analytes. The 
eluate was then dried under the stream of nitrogen gas, final volume was made up to 2 ml with methanol and 20 µl 
was introduced into the HPLC system.  
2.7. Chromatographic conditions optimizations 
Different chromatographic parameters like mobile phase composition ratio, flow rate, wavelengths of detector, 
injection volumes, internal standard and extraction solvents were optimized for quantitative determination of the 
meloxicam and its metabolites, using RP-HPLC method in an isocratic mode. 
 
2.7.1. Mobile phase composition 
A number of organic solvents such as acetonitrile, methanol, trifluoroacetic-acid (TFA), phosphate buffer, pH 
adjusted distilled water were tried in different combinations both in gradient and in an isocratic mode for the 
determination of the meloxicam and its metabolites. The mobile phase composition which demonstrated good 
resolution and separation was selected for analysis. 
2.7.2. Flow rate composition 
The flow rate significantly affect the sample elution, resolution, separation and peak shape. In this method flow rates 
in different ranges i.e. 0.8-1.5ml/min were evaluated and one that gave best resolution was selected as optimum flow 
rate. 
2.7.3. Detection wavelength  
A Perkin Elmer UV lambda (Nowak, USA) was used to determine the maximum wavelength of maximum 
DEVRUEDQFHȜmax) of meloxicam. Effect of wave length on analytes response was studied by varying wave length in 
the range of 330 ± 355 nm. 
2.7.4. Injection Volumes 
Different injection volumes in the ranges of 10 µl-50 µl were assessed using rheodyne manual injector. 
2.7.5. Internal standard selection  
Different internal standards such as naproxen sodium, lumefantrine, diclofenac-sodium, and piroxicam were tried. In 
present studies the Piroxicam showed maximum response and better chromatographic properties, therefore it was 
selected as internal standard. 
 
2.7.6. Selection of extraction solvent   
Various solvents such as diethyl-ether, dichloromethane, acetonitrile and n-hexane were evaluated as extraction 
solvents. Optimum percent recovery was achieved with dichloromethane as an extraction solvent. 
2.8. Validation of the method 
Validation of the developed method was carried out according to ICH guidelines with special emphasis on 
specificity, linearity, precision, accuracy, robustness, selectivity, limit of detection (LOD), and limit of quantification 
(LOQ) [17]. 
2.8.1. Specificity 
The specificity of developed method was judged from the complete peak resolution of the meloxicam and its 
metabolites in mobile phase, spiked biological sample in a 1:1 mixture (i.e. 1 µg/ml of the sample as well as internal 
standard). 
2.8.2. Linearity 
The linearity was evaluated by scheming calibration curves, at eight concentration level of meloxicam (10, 50, 100, 
250, 500, 1000, 1500 and 2000 ng/ml), 5-hydroxy meloxicam (30, 50, 75, 100, 250, 500, 750 and 1000 ng/ml), 5-
carboxy meloxicam (25, 50, 75, 100, 250, 500, 750 and 1000 ng/ml) and piroxicam (1000ng/ml). Following analysis, 
the ratios of peak area of the analyte and internal standard was plotted as function of the concentration of  analyte 
using the squares linear least regression equation and the correlation co-efficient.  
2.8.3. Accuracy 
The accuracy of the developed method was calculated from the percent recovery of the spiked sample. Blank human 
biological sample was spiked with analytes of different concentration levels keeping the concentration of I.S. 
constant. The similar concentrations levels were also prepared in mobile phase. Samples were then injected in 
triplicate and percent recoveries were calculated by the following equation: 
Percent recovery =  × 100 
Where  
A = Response ratio of the peak of spiked biological sample (analyte/I.S)  
B = Response ratio of the peak of sample in standard solution (analyte/I.S) 
2.8.4. Precision 
Precision of the developed method was determined by injection and the analysis repeatability. The injection precision 
repeatability was determined by injecting biological sample, spiked with 1000ng/ml of meloxicam, 5-carboxy 
meloxicam and 5-hydroxy meloxicam for 10 times into HPLC. The peak area and the retention time was obtained 
and articulated as mean, standard deviation (±SD), and covariance (% RSD). The precise analysis repeatability of the 
method was analyzed by spiking six biological samples with 1000 ng/ml of meloxicam, 5-carboxy meloxicam and 5-
hydroxy meloxicam, independently. 
Intermediate precision (i.e. intra-day and the inter-day studies) was determined by injecting plasma sample spiked 
with appropriate standard concentration of the analyte and internal standard on 8.0, 16.0 and 24.0 hours for three 
successive days. The outcome was depicted as mean, standard deviation as well as covariance and the following 
equation was employed to determine the concentration 
C =  CS DF 
Where  
x = Peak area of the analyte in biological sample 
y = Peak areas of the I.S in biological sample 
A = Peak area of the I.S in 1:1 mixture  
B = Peak area of the analyte in 1:1 mixture  
Cs = Concentration of analyte in the 1:1mixture 
DF = is the dilution factor 
2.8.5. Sensitivity 
The developed method sensitivity was assessed in terms of LOD and LOQ of analytes. The LOD was determined 
from the peak of the analyte by the software at which signal to noise ratio is 3 and the LOQ was concentration of the 
analyte at which signal to noise ratio is equal to10. 
2.8.6. Stability 
Stability studies of the meloxicam and its metabolites were assessed in spiked biological samples and standard stock 
solution at room temperature (25oC), refrigerator temperature (2-8oC) and at -20oC for one month. Each sample was 
then analyzed (n = 3) and the following equation was used to evaluate the stability: 
Percent Stability =  100 
 
Where 
St =Sample stability at that time  
So=Initial stability of sample  
2.8.7. Robustness/ Ruggedness 
The developed method robustness/ruggedness was investigated by bringing deliberately small alterations in 
chromatographic conditions, such as composition of the mobile phase (± 2%), temperature of the column oven (± 
5°C), mobile phase flow rate (± 0.2 ml/min) and detection wavelength (± 5%). 
3. Results and discussion 
The developed method for the analysis of meloxicam and its metabolites in human biological fluids using piroxicam 
as I.S is novel, fast, economical and sensitive. All the analytes and internal standard were completely resolved. 
Different chromatographic conditions and various experimental parameters of the developed method were optimized 
and validated according to ICH guidelines. According to literature it is first attempt to analyze the meloxicam and its 
metabolites simultaneously in biological samples. 
3.1 Sample preparation 
Meloxicam is sparingly soluble in methanol, ethanol, and however it was better in methanol that was further 
improved by the addition of 20µl of glacial acetic acid to about 10 ml of solution. The stock solution was then diluted 
with methanol. 
The protein in the plasma samples were precipitated with acetonitrile using three times of the plasma volume. The 
extraction of the analytes from the biological samples were carried out with dichloromethane, chloroform, ethyl 
acetate, diethyl ether, n-hexane either alone or with different combinations. Dichloromethane showed better percent 
recovery in both extraction procedure and was selected for extraction of analytes from the biological samples. 
3.2. Chromatographic conditions of the method 
3.2.1. Mobile phase and composition 
Different solvents such as acetonitrile, methanol, TFA, water and pH adjusted water were evaluated as mobile phases 
in different compositions. First acetonitrile and water (50: 50%v/v) as mobile phase was used, showed good shape 
and resolution of the peaks but retention time was not stable. The water was replaced with pH adjusted water in the 
range of 2 ± 4 and it ends with the same results of stability of retention time. Various ratio of the methanol: 
0.05%TFA was evaluated as the mobile phase to achieve better separation and stable chromatogram of the analytes. 
The results showed better resolution, peak shape and stability of the methods when methanol and TFA (0.05%) was 
used in 60:40% v/v. 
3.2.2. Flow rate 
The mobile flow rates ranges from 0.8-1.5% were applied; the optimum flow rate 1.3 ml/min was selected that gave 
good resolution of the analytes and total elution time was less than 7 min. 
3.2.3. Selection of the wavelength 
Wavelength 330 nm, 342 nm, 353 nm and 355 nm were evaluated and the best response for meloxicam, its 
metabolites and internal standard was observed at 353 nm. 
3.2.4. Selection of the internal standard 
Various compounds were assessed as internal standard that include naproxen sodium, diclofenac sodium, 
lumefantrine and piroxicam. Among these piroxicam showed good resolution, sensitivity, specificity, recovery, 
stability, and while other compounds were having long retention time or poor recovery. 
3.2.5. Selection of the column 
Thermo Quest Hypersil C18 column (250×4.6mm, 5µm; Run-corn, UK), Brownlee Perkin Elmer analytical C18 
(150×4.6mm, 5µm; Shelton, USA) column, Supelco/discovery C18 column (150x4.6mm, 5µm), Supelco/discovery 
C18 (250x4.6mm, 5µm) column and Thermo Quest Hypersil C8 (150×4.6mm, 5µm; Run-corn, UK) column were 
tried. The best resolution and other chromatographic properties were obtained with supelco discovery analytical C18 
column (150 x 4.6mm, 5µm). The representative chromatogram of the standard sample spiked with meloxicam, 5-
hydroxy, 5-carboxy meloxicam and I.S on the supelco/discovery C18 column is shown in Fig. 2. 
3.3. Method validation 
3.3.1. Linearity 
The calibration curves of meloxicam(10-2000 ng/ml), 5-hydroxy meloxicam (30-1000 ng/ml) and 5-carboxy 
meloxicam (25-1000 ng/ml) in  spiked biological samples  demonstrated excellent linearity ( r2 = 0.999) results are 
depicted in Table 1 and  in Fig. 3. 
 
3.3.2. Selectivity 
The selectivity of the method for the meloxicam and its metabolites was determined from a) mobile phase, b) blank 
plasma, urine and saliva c) plasma, urine, saliva sample spiked with meloxicam, 5-hydroxy meloxicam, 5-carboxy 
meloxicam and piroxicam as I.S, d) plasma, urine, saliva sample spiked with I.S. The Fig. 4, 5, 6 confirms the good 
resolution of the peaks and no other exogenous or endogenous peaks interfere with the chromatograms. 
3.3.3. Precision 
The precision results obtained from the injection repeatability and the intermediate precision (inter-day, intra-day 
studies) are summarized in Table 1 and 2. The method demonstrated good precision, the % RSD value for both inter-
day and intra-day which was less than 2%. 
3.3.4 Accuracy  
The developed method accuracy was assessed from the percent recovery, the mean percent recovery of meloxicam, 
5-hydroxy meloxicam, 5-carboxy meloxicam were 98.8%, 97.3%, 97% in plasma  99%, 98.6%, 95.1% in urine and 
95.8%, 92.9%, 92.7% in saliva by using liquid-liquid extraction and 92%, 84%, 77.8% in plasma, 93.4%, 87%, 
83.1% in urine, 85.5%, 78%, 74% in saliva by using solid-phase extraction showing %RSD value less than 1%, 
represents that the developed method was accurate. Percent recovery of all the analytes was higher with liquid-liquid 
extraction than SPE. 
3.3.5 Sensitivity 
The LOD for meloxicam, 5-hydroxy meloxicam and 5-carboxy meloxicam were 3ng, 10ng and 8ng, respectively. 
The LOQ were 9ng, 30ng and 25ng, respectively. Chromatograms of LLODs and LLOQs are shown in Fig. 7 and 
Fig. 8. 
 
 
3.3.6 Robustness 
The robustness of the developed method was verified by doing minor changes in chromatographic conditions such as 
composition of the mobile phase (± 0.3%), flow rate of the mobile phase (± 0.2 ml/min), wavelength (± 3 nm), did 
not substantially affect peak shape and the retention time of the sample. 
3.3.7 Stability 
The spiked plasma samples were stable for I week under all of the conditions; room temperature (25oC), refrigerated 
(2 ± 8oC) or frozen at (-80oC), while the standard solutions were stable for about a month when stored at 2 ± 8oC. 
4. Application of the method 
7KH SURSRVHG PHWKRG LV D SDUW RI FRPSUHKHQVLYH FOLQLFDO VWXG\ RQ ³3KDUPDFRNLQHWLF GUXJ-drug interaction of 
meloxicam, 5-hydroxy meloxicam and 5-carboxy meloxicam with commonly co-prescribed drugs like omeprazole 
DQGIOXFRQD]ROHLQKHDOWK\KXPDQYROXQWHHUV´7KHGHYHORSHGPHWKRGZDVVXFFHVVIXOO\DSSOLHGIRUWKHGHWHUPLQDWLRQ
of meloxicam in healthy human volunteers. Pharmacokinetic data was analyzed by using PK summit® software and 
will be published somewhere else. In all the analyzed plasma, saliva samples both metabolites 5-hydroxy meloxicam 
and 5-carboxy meloxicam concentrations were below the detection limit and thus could not be quantified and were 
only quantified in urine. This method was applied to the ongoing clinical trial and can also be employed for the 
quantification of meloxicam in various pharmaceutical dosage form as well. 
5. Conclusion  
The present developed method was optimized and validated for the simultaneous determination of meloxicam, 5-
hydroxy meloxicam and 5-carboxy meloxicam in human biological fluids. The method was simple, rapid, easy, 
accurate, precise and economical. Various chromatographic conditions were optimized for the analysis of these 
analytes according to standard guidelines. The effects of composition of the mobile phase, flow rate, temperature of 
the column oven, detection wavelength were studied. In this method meloxicam and its metabolites recovery was 
excellent from biological sample by using two step LLE procedures. All the peaks appear within 7 min in a single 
chromatographic run. This method can also be employed in various pharmaceutical dosage forms, in biological 
matrices and in pharmacokinetic studies. 
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Table-2: Accuracy, linearity, calibration, sensitivity, repeatability of the current RP-HPLC method. 
Parameters 
Plasma 
Urine Saliva 
Meloxica
m 
  5-
Hydroxy 
Meloxica
m 
5-
Carboxy 
Meloxica
m 
Meloxica
m 
5-
Hydroxy 
Meloxica
m 
5-
Carboxy 
Meloxica
m 
Meloxica
m 
5-
Hydroxy 
Meloxica
m 
5-
Carboxy 
Meloxica
m 
 
Accuracy (% recovery) 
Spiked concentration 1a 
(mean ± SD) 
Spiked concentration 2a 
(mean ± SD) 
Spiked concentration 3a 
(mean ± SD) 
Accuracy (% RSD) 
  Spiked concentration 1a 
  Spiked concentration 2a 
  Spiked concentration 3a 
 
Calibrations range (ng. mL-1) 
 
Linearity 
  Spiked samples 
    Slope (b) 
    Intercept (a) 
    Correlation-coefficient (r) 
 
 
5HSHDWDELOLW\¶V 
Injection repeatability (mean; 
%RSD) Spiked concentration 
3b 
Spiked concentration 3b 
Analysis repeatability 
(mean;%RSD) 
    Spiked concentration 3b 
 
Sensitivity 
Lower limit of the detection, 
LLOD  
(ng.mL-1) 
Lower limit of the 
quantification, LLOQ 
(ng.mL-1)  
 
 
99.12±0.
219 
98.49±0.
373 
98.83±0.
529 
 
0.70 
0.54 
0.38 
 
10.0-
2000.0 
 
 
 
0.002 
0.0102 
0.9999 
 
 
 
 
c 6.16.; 
0.53 
d162652; 
1.25 
 
d163084; 
0.75 
 
 
3.0 
 
9.0 
 
 
97.24±0.
311 
97.91±0.
566 
96.75±0.
758 
 
0.59 
0.41 
0.29 
 
30.0-
1000.0 
 
 
 
0.0006 
0.0031 
0.9997 
 
 
 
 
c 2.72; 
0.33 
d 49475; 
0.87 
 
d49371; 
0.41 
 
 
10.0 
 
32.0 
 
 
95.54±0.
298 
97.62±0.
471 
98.11±0.
883 
 
0.54 
0.38 
0.32 
 
25.0-
1000.0 
 
 
 
0.0012 
0.0015 
0.9991 
 
 
 
 
C4.36; 
0.24 
d79063; 
0.93 
 
d78269; 
0.39 
 
 
8.0 
 
25.0 
 
 
98.51±0.
372 
99.59±0.
619 
99.08±0.
944 
 
0.81 
0.63 
0.41 
 
10-
2000.0 
 
 
 
0.0002 
0.0664 
0.9996 
 
 
 
 
c 6.17.; 
0.58 
d159548; 
1.77 
 
d160856; 
0.91 
 
 
3.0 
 
9.0 
 
 
99.66±0.
421 
99.82±0.
737 
99.32±0.
895 
 
0.69 
0.49 
0.33 
 
30-
1000.0 
 
 
 
0.0006 
0.0138 
0.9995 
 
 
 
 
c 2.71; 
0.36 
d 50342; 
1.01 
 
d52597; 
0.52 
 
 
10.0 
 
32.0 
 
 
96.48±0.
408 
95.10±0.
582 
93.98±0.
817 
 
0.58 
0.43 
0.38 
 
25.0-
1000.0 
 
 
 
0.0011 
0.0001 
0.9997 
 
 
 
 
C4.37; 
0.26 
d74274; 
0.96 
 
d76568; 
0.44 
 
 
8.0 
 
25.0 
 
 
97.85±0.
335 
94.67±0.
541 
95.09±0.
786 
 
0.84 
0.66 
0.47 
 
10.0-
2000.0 
 
 
 
0.0018 
0.0477 
0.9993 
 
 
 
 
c 6.16.; 
0.49 
d150548; 
1.11 
 
d148357; 
0.72 
 
 
3.0 
 
9.0 
 
 
92.86±0.
317 
90.93±0.
493 
94.78±0.
655 
 
0.72 
0.52 
0.43 
 
30.0-
1000.0 
 
 
 
0.0005 
0.0026 
0.9997 
 
 
 
 
c 2.73; 
0.29 
d 41231; 
0.92 
 
d40217; 
0.47 
 
 
10.0 
 
32.0 
 
 
94.32±0.
368 
91.41±0.
629 
92.23±0.
904 
 
0.62 
0.48 
0.42 
 
25.0-
1000.0 
 
 
 
0.001 
0.0008 
0.9996 
 
 
 
 
C4.36; 
0.32 
d69584; 
1.17 
 
d70482; 
0.41 
 
 
8.0 
 
25.0 
  
Spiked concentration 1= meloxicam: 50ng.mL-1, 5-hydroxy meloxicam: 50ng.mL-1and 5-carboxy meloxicam: 
50ng.mL-1; Spiked concentration 2 = meloxicam: 100 ng.mL-1, 5-hydroxy meloxicam: 100ng.mL-1 and 5-carboxy 
meloxicam: 100ng.mL-1; Spiked concentration 3 = meloxicam:1000ng.mL-1, 5-hydroxy meloxicam: 1000ng.mL-1and 
5-carboxy meloxicam: 1000ng.mL-1.a n= 5, bn= 10, cRetention time (min), dPeak area, e Amount recovered. 
 
 
 
 
 Table-2: The data of the Intra days and Inter days Precision (n = 3). 
Concentra
tion spiked 
(ng.mL-1)  
Plasma concentration(ng.mL-1) 
 
Urine concentration (ng.mL-1) 
 
Saliva concentration (ng.mL-1) 
 
Intra day 
(mean±S.D) 
% 
RS
D 
Inter day 
(mean±S.D) 
% 
RSD 
Intra day 
(mean±S.D) 
% 
RS
D 
Inter day 
(mean±S.D) 
% 
RS
D 
Intra day 
(mean±S.D) 
% 
RS
D 
 
Inter day 
(mean±S.D) RS
 
 
Meloxicam 
   50.0 
   100.0 
   2000.0 
 
 5-Hydroxy    
meloxicam 
   50.0 
   100.0 
   1000.0 
 
 5-Carboxy 
meloxicam 
  50.0 
  100.0 
  1000.0 
 
 
 
49.552±0.26
07 
98.286±0.43
77 
1979.658±2.
8924 
 
 
 
48.698±0.21
52 
97.712±0.30
78 
966.274±1.0
560 
 
 
 
48.214±0.81
90 
96.035 ± 
1.1503 
973.050±2.6
483 
 
 
 
 
0.52
61 
0.44
54 
0.14
61 
 
 
 
0.44
19 
0.31
50 
0.10
93 
 
 
 
1.70
18 
1.19
78 
0.27
21 
 
 
 
 
49.297±0.36
33 
97.116±0.59
65 
1949.466±2.
889 
 
 
 
48.127±0.46
99 
96.850±0.69
99 
960.839±1.4
980 
 
 
 
47.755±0.84
60 
94.910±1.25
69 
968.464±1.4
671 
 
 
 
 
0.73
69 
0.61
42 
0.14
82 
 
 
 
0.97
63 
0.72
26 
0.15
59 
 
 
 
1.77
15 
1.32
43 
0.15
15 
 
 
 
 
49.258±0.391
1 
99.312±0.724
3 
1975.490±1.9
962 
 
 
 
49.696 
±0.3741 
99.388±0.781
6 
995.449±0.99
81 
 
 
 
48.037 
±0.4933 
96.821 ± 
0.8662 
944.966±1.08
92 
 
 
 
 
0.79
39 
0.72
93 
0.10
10 
 
 
 
0.75
25 
0.78
64 
0.10
02 
 
 
 
1.02
69 
0.89
46 
0.11
52 
 
 
 
 
48.987±0.45
21 
98.045±0.81
17 
1952.656±2.
5431 
 
 
 
49.258 
±0.5494 
99.131±0.91
46 
990.507±2.3
118 
 
 
 
47.488 
±0.7372 
96.114 ± 
1.3742 
940.339±1.4
611 
 
 
 
 
0.92
28 
0.82
78 
0.13
02 
 
 
 
1.11
53 
0.92
26 
0.23
33 
 
 
 
1.55
23 
1.42
97 
0.15
54 
 
 
 
 
48.729±0.41
49 
95.298±0.69
80 
1900.486±2.
6626 
 
 
 
46.578 
±0.2376 
93.319±0.46
49 
949.996±2.9
781 
 
 
 
47.328 
±0.5916 
94.536 ± 
0.7864 
919.327±1.1
232 
 
 
 
 
0.85
14 
0.73
24 
0.14
01 
 
 
 
0.51
01 
0.49
81 
0.31
34 
 
 
 
1.25
00 
0.83
18 
0.12
21 
 
 
 
 
48.455±0.56
54 
94.513±0.91
20 
1896.724±2.
7223 
 
 
 
45.824 
±0.1855 
92.857±0.49
63 
942.383±2.3
756 
 
 
 
46.674 
±0.3117 
93.288 ± 
0.9833 
913.407±1.3
686 
 
 
 
 
1
68
0
0
0
48
0
0
0
78
1
0
98
 
 
 
 
  
 
 
Figure 1: Structures; A) meloxicam, B) 5-hydroxy meloxicam, C) 5-carboxy meloxicam. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 2: The chromatogram of standard sample spiked with 100 ng/ml of meloxicam (peak -4), 75 ng/ml of each 
metabolite i.e 5-hydroxy meloxicam (peak-1); 5-carboxy meloxicam (peak-3) and 1000ng/ml of internal standard 
(peak-2). 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 3: Calibration curves of (A) meloxicam, (B) 5-hydroxy meloxicam, (C) 5-carboxy meloxicam. Solid lines 
ʊUHSUHVHQW spiked plasma, dashed lines (---) represent spiked urine and dotted lineV«UHSUHVHQW spiked saliva. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 4: HPLC FKURPDWRJUDP¶VRIYDULRXV samples, Peak-1; 5-hydroxy meloxicam, 2; internal standard, 3; 5-
carboxy meloxiFDPPHOR[LFDP&KURPDWRJUDP¶V a; blank-solvent, b; blank-plasma, c; plasma spiked sample with 
1000ng/ml of meloxicam, 500ng/ml of 5-hydroxy meloxicam, 500ng/ml of 5-carboxy meloxicam and 1000ng/ml of 
internal standard, d; plasma sample. 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 5: HPLC chromatogram¶V RI YDULRXV samples, Peak-1; 5-hydroxy meloxicam, 2; internal standard, 3; 5-
carboxy meloxicam, 4; meloxicam. Chromatogram¶V D EODQN-solvent, b; blank-urine, c; urine spiked sample with 
1000ng/ml of meloxicam, 500ng/ml of 5-hydroxy meloxicam, 500ng/ml of 5-carboxy meloxicam and 1000ng/ml of 
internal standard, d; urine sample. 
. 
 
 
 
 
 
 
 
         
 
 
Figure 6: HPLC chromatogram¶V RI YDULRXV samples, Peak-1; 5-hydroxy meloxicam, 2; internal standard, 3; 5-
carboxy meloxicam, 4; meloxicam. Chromatogram¶VDEODQN-solvent, b; blank-saliva, c; saliva spiked sample with 
1000ng/ml of meloxicam, 500ng/ml of 5-hydroxy meloxicam, 500ng/ml of 5-carboxy meloxicam and 1000ng/ml of 
internal standard, d; saliva sample. 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 7: HPLC chromatogram showing peaks of 5-hydroxy meloxicam (peak-1), 5-carboxy meloxicam (peak-3) 
and meloxicam (peak-4) at the lower limit of detection. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 8: HPLC chromatogram showing peaks of 5-hydroxy meloxicam (peak-1), 5-carboxy meloxicam (peak-3) 
and meloxicam (peak-4) at the lower limit of quantification. 
 
 
 
 
 
